Meeting
2022 ASCO Gastrointestinal Cancers Symposium
Exploration of drug resistance in advanced gastrointestinal stromal tumor.
Authors
Hao Xu
Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
Hao Xu , Zekuan Xu , Jianghao Xu , Yang Shao
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Tumor Biology, Biomarkers, and Pathology
DOI
10.1200/JCO.2022.40.4_suppl.662
Abstract #
662
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
KIT resistance mutations identified by circulating tumor DNA and treatment outcomes in advanced gastrointestinal stromal tumor.
First Author: Steven Bialick
Poster
2023 ASCO Annual Meeting
Outcomes in patients with advanced gastrointestinal stromal tumor who did not have baseline ctDNA detected in the INTRIGUE study.
First Author: Jonathan C. Trent
Poster
2018 ASCO Annual Meeting
Phase Ib study of rapid alternation of sunitinib (SU) and regorafenib (RE) in patients (pts) with advanced gastrointestinal stromal tumor (GIST).
First Author: Cesar Serrano
Poster
2013 ASCO Annual Meeting
In vitro and in vivo activity of regorafenib (REGO) in drug-resistant gastrointestinal stromal tumors (GIST).
First Author: Cesar Serrano-Garcia